Rucaparib is a potent PARP-1 and PARP-2 oral inhibitor, which is approved by FDA in December 2016 and by EMA in May 2018 as monotherapy for the treatment of advanced BRCA-mutated ovarian cancer, relapsed after at least two chemotherapy lines. This evidence concerns the gene PARP1 and ovarian carcinoma.